Mind Medicine (MindMed) Inc. MNMD
20.69 USD 0.00 (+0.00%)
Apr 2, 2026, 3:59 PM EDT
19.95 Day range 21.10
52-week range unavailable
- YTD
- +54.52%
- 1 year
- +219.78%
News
benzinga.com FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order https://www.hhs.gov/press-room/fda-accelerates-action-treatments-serious-mental-illness-following-executive-order.html
benzinga.com 'Bipartisan Senators File Bill To Support Psychedelics Research And Treatment For Veterans' - Marijuana Moment https://www.marijuanamoment.net/bipartisan-senators-file-bill-to-support-psychedelics-research-and-treatment-for-veterans/
defenseworld.net Short Interest in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Grows By 19.4% Mind Medicine (MindMed) Inc. (NASDAQ: MNMD - Get Free Report) saw a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling…
seekingalpha.com Mind Medicine (MindMed) Inc. (MNMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Mind Medicine (MindMed) Inc. (MNMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
defenseworld.net Mind Medicine (MindMed) (NASDAQ:MNMD) CEO Robert Barrow Sells 25,791 Shares of Stock Mind Medicine (MindMed) Inc. (NASDAQ: MNMD - Get Free Report) CEO Robert Barrow sold 25,791 shares of the business's stock in a transaction on Friday, December 26th. The shares were sold at an…
zacks.com MNMD Stock Up More Than 100% in 6 Months: What's in Store for 2026? MNMD has surged 101% in six months with MM120 advancing in phase III for GAD and MDD. Pivotal readouts are slated for 2026.
defenseworld.net Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Average Rating of “Buy” from Analysts Mind Medicine (MindMed) Inc. (NASDAQ: MNMD - Get Free Report) has received a consensus rating of "Buy" from the twelve analysts that are presently covering the stock, MarketBeat.com reports. One…
businesswire.com MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain…
zacks.com 5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026 After a weak first half, the drug and biotech sector has recovered in the past 2-3 months with large drugmakers like Pfizer, AstraZeneca, Eli Lilly and Novo Nordisk signing drug pricing agreements…
businesswire.com MindMed Announces New Employee Inducement Grant NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain…
businesswire.com MindMed Announces New Employee Inducement Grants NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain…
defenseworld.net Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Average Recommendation of “Buy” from Analysts Shares of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD - Get Free Report) have received an average recommendation of "Buy" from the eleven research firms that are currently covering the company,…
seekingalpha.com Mind Medicine (MindMed) Inc. (MNMD) Q3 2025 Earnings Call Transcript Mind Medicine (MindMed) Inc. ( MNMD ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Robert Barrow - CEO & Director Daniel Karlin - Chief Medical Officer Brandi Roberts -…
businesswire.com MindMed Reports Q3 2025 Financial Results and Business Updates NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat…
benzinga.com Earnings Scheduled For November 6, 2025 
businesswire.com MindMed to Participate in Upcoming Investor Conferences NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain…
businesswire.com MindMed Announces New Employee Inducement Grant NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain…
businesswire.com Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain…
businesswire.com Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain…
businesswire.com Mind Medicine (MindMed) Inc. Announces Proposed Public Offering NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain…
businesswire.com MindMed Announces New Employee Inducement Grant NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain…
seekingalpha.com MindMed Nears Pivotal Year: Strong Fundamentals Make It A Buy Mind Medicine (MNMD) is advancing its lead drug MM120 through Phase 3 trials for anxiety and depression, positioning for long-term upside. MNMD's strong cash reserves, disciplined spending, and…
thefly.com Mind Medicine initiated with an Outperform at LifeSci Capital LifeSci Capital analyst Francois Brisebois initiated coverage of Mind Medicine with an Outperform rating and $32 price target.
benzinga.com The Insider Report: Panic Never Pays 
benzinga.com Earnings Scheduled For July 31, 2025 - benzinga.com 'House Votes To Let VA Doctors Recommend Medical Marijuana To Military Veterans And To Support Psychedelics Research' - Marijuana Moment https://www.marijuanamoment.net/house-votes-to-let-va-doctors-recommend-medical-mari
benzinga.com "RFK Says Trump Administration Could Provide Psychedelic Therapy To Military Veterans 'Within 12 Months'" - Marijuana Moment https://www.marijuanamoment.net/rfk-says-trump-administration-could-provide-psychedelic-therapy-to-military-veterans-within-12-months/
benzinga.com 'Psychedelics Proponents Hope Trump Administration Will Foster A New Era' - STAT News https://www.statnews.com/2025/06/18/fda-approval-psychedelics-rfk-jr-trump-allies-see-opening-mdma-psilocybin-mental-health-treatment/- benzinga.com Reported June 17, 2025: 'Alaska Activists Launch Campaign To Put Psychedelics Legalization Measure On 2026 Ballot' - Marijuana Moment https://www.marijuanamoment.net/alaska-activists-launch-campaign-to-put-psychedelics-legalization-measure-on-2026-ballot/
- benzinga.com 'Texas Governor Signs Bill To Create Ibogaine Research Consortium, Aiming To Develop FDA-Approved Psychedelic Drug' - Marijuana Moment https://www.marijuanamoment.net/texas-governor-signs-bill-to-create-ibogaine-research-consortium-aiming-to-develop-fda-approved-psychedelic-drug/
benzinga.com "Colorado Governor Says Bill He Signed Allowing Psychedelic Convictions To Be Pardoned Marks A Step 'Towards A Fairer Future'" - Marijuana Moment https://www.marijuanamoment.net/colorado-governor-says-bill-he-signed-allowing-psychedelic-convictions-to-be-pardoned-marks-a-step-towards-a-fairer-future/- benzinga.com 'Doctor Seeking To Reschedule Psilocybin To Treat Dying Patients Demands DEA Update After Agency Agreed To Initiate Federal Review' - Marijuana Moment https://www.marijuanamoment.net/doctor-seeking-to-res
benzinga.com Agilysys, Amer Sports, X Financial And Other Big Stocks Moving Higher On Tuesday - benzinga.com Earnings Scheduled For May 8, 2025
- benzinga.com Earnings Scheduled For March 6, 2025
benzinga.com Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - benzinga.com DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
benzinga.com Why Stitch Fix Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - benzinga.com Seritage Growth Properties Posts Q1 Loss, Joins Fortrea Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
- benzinga.com Roblox, TAL Education And Other Big Stocks Moving Higher On Wednesday U.S. stocks were lower, with the Dow Jones index falling over 300 points on Wednesday.
benzinga.com Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24…- benzinga.com Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Shares of HighPeak Energy, Inc. (NASDAQ: HPK) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter revenue results.
- benzinga.com Earnings Scheduled For February 28, 2024 Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion.
- benzinga.com Earnings Scheduled For November 2, 2023 Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million.
- benzinga.com Earnings Scheduled For August 3, 2023 Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.
- benzinga.com Earnings Scheduled For May 4, 2023 Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss at $1.83 per share on revenue of $104.21 million.
- benzinga.com Why Teva Pharmaceutical Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Friday's Mid-Day Session Gainers SAI.TECH Global Corporation (NASDAQ: SAI) jumped 269% to $5.61 after gaining around 25% on Thursday.
benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 116 companies set new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 258 companies hit new 52-week lows.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For November 16, 2022 Upgrades